Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
about
Fractional proliferation: a method to deconvolve cell population dynamics from single-cell dataEpidermal Growth Factor Receptor: A Novel Target for Anticancer TreatmentEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysisHPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinomaAntitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Novel molecular imaging platform for monitoring oncological kinases.Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.Imaging of epidermal growth factor receptor on single breast cancer cells using surface-enhanced Raman spectroscopyOverexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis.Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.Phenotypic variation resulting from a deficiency of epidermal growth factor receptor in mice is caused by extensive genetic heterogeneity that can be genetically and molecularly partitionedNovel therapeutic strategies for targeting liver cancer stem cells.Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models.Association between the epidermal growth factor +61 G/A polymorphism and glioma risk: a meta-analysis.Molecular imaging of epidermal growth factor receptor kinase activity.Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.Treatment of advanced non small cell lung cancer.EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivativesTyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.Epidermal growth factor inhibition in solid tumours.Current status of cetuximab for the treatment of patients with solid tumors.Epidermal growth factor receptor inhibitors in cancer treatment.Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerDiffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.Recent developments in colorectal cancer treatment by monoclonal antibodies.A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumorsA Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.HER family inhibitors in pancreatic cancer: current status and future directions.Estimating Individualized Treatment Rules Using Outcome Weighted Learning
P2860
Q24633509-C84C0C69-B5EE-41F7-B87B-597AC4DD34EDQ24800380-E734AD83-A865-4825-9E09-5C25B78E7144Q30313117-7A60697D-89EA-4B3C-B863-D01C6393644BQ30430971-AA4B7167-3631-4C75-864C-2533BFA49FD2Q30683030-6D62C62D-EEB2-41D9-B571-3E142094F7D1Q33284494-8A6922EC-5418-4E3A-9EB5-B1978D3FA4D9Q33289414-8D1BA20E-3DFF-4EA0-A746-55127221D9BAQ33421419-2594FDBC-3D02-4262-B468-B1646EBF8F53Q33586269-04BFEF79-00B0-4777-8FF2-C6B92BD44BB0Q33744196-D4A79F86-E7FA-4851-AFD7-41F3507D83E0Q33753716-78E7E487-4CF9-4076-A5DE-011E8B44B736Q33983663-7ABB3660-8C67-4533-A37E-2F2AA8C91FC0Q34039242-2AE02CE6-9205-42BE-B2DB-989EC17B4E20Q34067821-AF706A21-9B07-4048-8AA8-7512BF9B57B6Q34205467-1E821A4E-C3CD-4BB8-BD85-E489264658F9Q34328127-5F630664-A332-49D2-A02A-08BB913643B7Q34361442-FD0BA064-608E-41B5-983E-E6166C2AA835Q34414026-FFA8F102-DA24-4842-B36C-C0B64C95CDFAQ34645600-E9633EE0-7BF2-4881-B86F-6CD05AFD52C0Q34940971-88A45DAA-0E53-4E69-AA71-C0AE89B169EBQ35026818-8E31722F-98A2-4151-8631-D737DE688BEAQ35150484-27D7DFBD-C8C3-4A11-9F36-9CB89ECE8B0AQ35486243-859EFE37-0493-457A-9FE0-1A568B3167DCQ35571884-8E171C96-62D3-40A6-8E0D-994327169BD3Q35576159-9E68EF02-0D00-4D05-AB79-4F43AA12F797Q35602676-A27EF6E6-7956-4E6F-81F6-1AA7AD559467Q35667817-A2ADEB72-3283-4E00-8DDC-133B44F6D0D3Q35729147-B0DAD4EC-2C9A-47E0-B090-B728240E8186Q35946822-279406AD-8864-4918-A995-CD988521C588Q36225230-F8CFB5BB-FE32-441A-9C52-2729D9E49FC0Q36239648-9A841D60-2E54-4B78-8D30-4E2AC4FC96F1Q36364973-28671699-04F4-4E51-8206-7BA085FDDA55Q36429442-07492BBE-A129-438F-B319-B1EE14D3367CQ36614337-8DB8CD49-635B-4996-B076-5F07E8A950C6Q36614881-B92B075C-3CA4-41E0-87A3-326AC50E5008Q36627254-91EB13A6-AEEA-46C5-BB82-D8524E119EE7Q36660463-D4BBFAD8-4A25-4B4D-96A2-9426ACE95851Q36660538-2ADD9EBC-D67D-48A0-9807-F7F1DBC9FD47Q36734936-B9E05AA4-0CD7-4BC4-AE6D-CFF6E10DCA70Q36796669-DBBB66EA-DEF8-4BA0-B284-0EB60E5C43D5
P2860
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
@ast
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
@en
type
label
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
@ast
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
@en
prefLabel
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
@ast
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
@en
P2860
P356
P1476
Developing inhibitors of the epidermal growth factor receptor for cancer treatment
@en
P2093
Viktor Grünwald
P2860
P304
P356
10.1093/JNCI/95.12.851
P407
P577
2003-06-01T00:00:00Z